SCHEMBL23896274

SCHEMBL23896274

O=C(O)C12CC(C1)C(Nc1nc3cc(O)ccc3c(-c3ccc(F)cc3)c1C1CCOCC1)C2

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.33
HDAC2 Q92769 2/20 0.33
ESR1 P03372 2/20 0.33
PRKAA2 P54646 2/20 0.32
PRKAB2 O43741 1/20 0.32
PRKAG1 P54619 1/20 0.32
PRKAA1 Q13131 1/20 0.32
PRKAG3 Q9UGI9 1/20 0.32
PRKAG2 Q9UGJ0 1/20 0.32
PRKAB1 Q9Y478 1/20 0.32
GABBR2 O75899 1/20 0.30
GABBR1 Q9UBS5 1/20 0.30
ABL1 P00519 1/20 0.30
JAK1 P23458 1/20 0.30
JAK3 P52333 1/20 0.30
MAP4K4 O95819 1/20 0.30
MAPK8 P45983 1/20 0.30
MAPK10 P53779 1/20 0.30
MAPK14 Q16539 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23887789 0.84 HDAC1 (0.35) HDAC1HDAC2ESR1PRKAA2PRKAB2
SCHEMBL23896112 0.80 ESR1 (0.34) HDAC1HDAC2ESR1PRKAA2
SCHEMBL23896107 0.79 PDE10A (0.36) HDAC1HDAC2ESR1
SCHEMBL23896110 0.79 EGLN2 (0.36) HDAC1HDAC2ESR1PRKAA2
SCHEMBL23895810 0.79 PDE10A (0.36) HDAC1HDAC2ESR1
SCHEMBL25562886 0.77 NR1I2 (0.36) HDAC1HDAC2ESR1PRKAA2
SCHEMBL23896399 0.77 ESR1 (0.33) HDAC1HDAC2ESR1PRKAA2MAP4K4
SCHEMBL25544781 0.77 HDAC1 (0.33) HDAC1HDAC2ESR1ABL1
SCHEMBL23896102 0.77 NR1I2 (0.36) HDAC1HDAC2ESR1PRKAA2
SCHEMBL23896402 0.77 NR1I2 (0.36) HDAC1HDAC2ESR1PRKAA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021203028-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-10-07 WO disclosed